FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2068331348> ?p ?o ?g. }

• W2068331348 endingPage "54" @default.
• W2068331348 startingPage "47" @default.
• W2068331348 abstract "The active morphine metabolite, morphine-6-glucuronide (M-6-G), may contribute to both the analgesia and the adverse effects observed during morphine (MOR) therapy. To evaluate the relationship between M-6-G and adverse effects, we measured steady-state plasma concentrations of MOR and M-6-G and concurrently noted the presence or absence of moderate to severe cognitive impairment or myoclonus in 109 cancer patients who were receiving either oral (n = 71) or parenteral (n = 38) morphine. MOR and M-6-G plasma concentrations were determined by HPLC with electrochemical detection. The presence of cognitive impairment or myoclonus was analyzed in relation to molar M-6-G/MOR ratio, age, morphine dose, the use of other centrally acting drugs, renal function (blood urea nitrogen (BUN) and serum creatinine), hepatic function (serum bilirubin, serum glutamic oxalacetic transaminase (SGOT), and alkaline phosphotase) and serum lactate dehydrogenase (LDH). The patient population consisted of 60 women and 49 men. The mean age was 51.5 years (range: 10–85 years). The mean morphine dose (total dose-prior 48 h) was 486 mg (range: 40–4800 mg) for the oral group and 931 mg (range: (10–9062 mg) for the parenteral group. The mean molar M-6-G/MOR ratios were 6.1 (SD: 18.2; range: 0.01–153.3) for the oral treatment group and 2.7 (SD: 4.16; range: 0.05–23.8) for the parenteral treatment group. Overall, the M-6-G/MOR ratio demonstrated a moderate but significant correlation with BUN (r = 0.4; P < 0.001) and creatinine (r = 0.45; P < 0.001) levels, but not with the other clinical variables examined. Although the prevalence of myoclonus among patients receiving oral morphine was 3-fold higher than those receiving parenteral morphine (P < 0.05), multivariate analyses demonstrated that neither myoclonus nor cognitive impairment was significantly associated with M-6-G/MOR ratio when adjusted for other variables. In contrast, there were significant associations between increasing age, elevated bilirubin or LDH levels, and the presence of cognitive impairment. Finally, analysis of a small subgroup of patients with very high M-6-G concentrations (> 2000 ng/ml) and presenting with either respiratory depression or obtundation, suggested that elevated M-6-G levels were associated with these severe adverse effects primarily in the setting of metabolic dysfunction. Together, these data confirm the previously reported correlation between deteriorating renal function and increasing M-6-G/MOR ratio, but do not support the conclusion that increasing ratio alone is a determinant of two prevalent opioid-related adverse effects: myoclonus and cognitive impairment." @default.
• W2068331348 created "2016-06-24" @default.
• W2068331348 creator A5019490398 @default.
• W2068331348 creator A5020101797 @default.
• W2068331348 creator A5032744554 @default.
• W2068331348 creator A5067118176 @default.
• W2068331348 creator A5083219961 @default.
• W2068331348 creator A5090628353 @default.
• W2068331348 date "1995-04-01" @default.
• W2068331348 modified "2023-10-18" @default.
• W2068331348 title "Morphine-6-glucuronide concentrations and opioid-related side effects: a survey in cancer patients" @default.
• W2068331348 cites W1970520180 @default.
• W2068331348 cites W1976204482 @default.
• W2068331348 cites W1996565727 @default.
• W2068331348 cites W2006674934 @default.
• W2068331348 cites W2006908055 @default.
• W2068331348 cites W2007282407 @default.
• W2068331348 cites W2014219816 @default.
• W2068331348 cites W2016169214 @default.
• W2068331348 cites W2023187279 @default.
• W2068331348 cites W2028064281 @default.
• W2068331348 cites W2038635568 @default.
• W2068331348 cites W2060435731 @default.
• W2068331348 cites W2065548294 @default.
• W2068331348 cites W2080843499 @default.
• W2068331348 cites W2094725656 @default.
• W2068331348 cites W2097670677 @default.
• W2068331348 cites W2434761725 @default.
• W2068331348 doi "https://doi.org/10.1016/0304-3959(94)00148-8" @default.
• W2068331348 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7644248" @default.
• W2068331348 hasPublicationYear "1995" @default.
• W2068331348 type Work @default.
• W2068331348 sameAs 2068331348 @default.
• W2068331348 citedByCount "141" @default.
• W2068331348 countsByYear W20683313482012 @default.
• W2068331348 countsByYear W20683313482013 @default.
• W2068331348 countsByYear W20683313482014 @default.
• W2068331348 countsByYear W20683313482015 @default.
• W2068331348 countsByYear W20683313482016 @default.
• W2068331348 countsByYear W20683313482017 @default.
• W2068331348 countsByYear W20683313482018 @default.
• W2068331348 countsByYear W20683313482019 @default.
• W2068331348 countsByYear W20683313482020 @default.
• W2068331348 countsByYear W20683313482021 @default.
• W2068331348 countsByYear W20683313482022 @default.
• W2068331348 countsByYear W20683313482023 @default.
• W2068331348 crossrefType "journal-article" @default.
• W2068331348 hasAuthorship W2068331348A5019490398 @default.
• W2068331348 hasAuthorship W2068331348A5020101797 @default.
• W2068331348 hasAuthorship W2068331348A5032744554 @default.
• W2068331348 hasAuthorship W2068331348A5067118176 @default.
• W2068331348 hasAuthorship W2068331348A5083219961 @default.
• W2068331348 hasAuthorship W2068331348A5090628353 @default.
• W2068331348 hasConcept C126322002 @default.
• W2068331348 hasConcept C159641895 @default.
• W2068331348 hasConcept C160160445 @default.
• W2068331348 hasConcept C170493617 @default.
• W2068331348 hasConcept C181199279 @default.
• W2068331348 hasConcept C185592680 @default.
• W2068331348 hasConcept C197934379 @default.
• W2068331348 hasConcept C2777389121 @default.
• W2068331348 hasConcept C2777513400 @default.
• W2068331348 hasConcept C2778176769 @default.
• W2068331348 hasConcept C2780306776 @default.
• W2068331348 hasConcept C2781063702 @default.
• W2068331348 hasConcept C2908647359 @default.
• W2068331348 hasConcept C55493867 @default.
• W2068331348 hasConcept C71924100 @default.
• W2068331348 hasConcept C90924648 @default.
• W2068331348 hasConcept C99454951 @default.
• W2068331348 hasConceptScore W2068331348C126322002 @default.
• W2068331348 hasConceptScore W2068331348C159641895 @default.
• W2068331348 hasConceptScore W2068331348C160160445 @default.
• W2068331348 hasConceptScore W2068331348C170493617 @default.
• W2068331348 hasConceptScore W2068331348C181199279 @default.
• W2068331348 hasConceptScore W2068331348C185592680 @default.
• W2068331348 hasConceptScore W2068331348C197934379 @default.
• W2068331348 hasConceptScore W2068331348C2777389121 @default.
• W2068331348 hasConceptScore W2068331348C2777513400 @default.
• W2068331348 hasConceptScore W2068331348C2778176769 @default.
• W2068331348 hasConceptScore W2068331348C2780306776 @default.
• W2068331348 hasConceptScore W2068331348C2781063702 @default.
• W2068331348 hasConceptScore W2068331348C2908647359 @default.
• W2068331348 hasConceptScore W2068331348C55493867 @default.
• W2068331348 hasConceptScore W2068331348C71924100 @default.
• W2068331348 hasConceptScore W2068331348C90924648 @default.
• W2068331348 hasConceptScore W2068331348C99454951 @default.
• W2068331348 hasIssue "1" @default.
• W2068331348 hasLocation W20683313481 @default.
• W2068331348 hasOpenAccess W2068331348 @default.
• W2068331348 hasPrimaryLocation W20683313481 @default.
• W2068331348 hasRelatedWork W1954166975 @default.
• W2068331348 hasRelatedWork W1973267410 @default.
• W2068331348 hasRelatedWork W2009214735 @default.
• W2068331348 hasRelatedWork W2020445939 @default.
• W2068331348 hasRelatedWork W2073638606 @default.
• W2068331348 hasRelatedWork W2100508540 @default.
• W2068331348 hasRelatedWork W2144732297 @default.

• next